A
Auxilium Pharmaceuticals
Develops and markets pharmaceutical products that focus on urology and sexual health
About Auxilium Pharmaceuticals
Auxilium Pharmaceuticals, Inc. was a specialty biopharmaceutical company founded in 1999 with a strategic focus on developing and marketing products for urology and men's health. The company established a significant market presence through a portfolio of 12 approved products, addressing conditions such as erectile dysfunction, testosterone replacement, and Peyronie's disease.
Key products in its commercial portfolio included XIAFLEX, a biologic treatment for Dupuytren's contracture and Peyronie's disease; Testim, a testosterone gel for hypogonadism; and TESTOPEL, an implantable testosterone replacement therapy. The company's business model revolved around the development and commercialization of these specialist-focused pharmaceutical products. A significant milestone was the 2013 acquisition of Actient Holdings LLC for $585 million, a move that created a more comprehensive urology platform and expanded its testosterone replacement therapy offerings.
In a culminating event for the company, Auxilium was acquired by Endo International plc in a transaction valued at approximately $2.6 billion, announced in October 2014 and completed in January 2015. This acquisition was positioned as a strategic move to enhance Endo's branded pharmaceuticals business by integrating Auxilium's complementary portfolio, particularly strengthening its offerings in urology and orthopedics. The deal followed Auxilium's rejection of an earlier, lower offer from Endo and the termination of a planned merger with QLT Inc. Following the acquisition, Auxilium's common stock ceased trading on the NASDAQ Global Market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 128
- Open positions
- None listed
- Dealroom signal
- 67.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Trading, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2014 | $2.6B | $2.6B | Endo Pharmaceuticals Inc | — |
| IPO✓Exit | Jul 2004 | $41M | $160M | Undisclosed | — |
Growth signals
Latest recorded traffic for Auxilium Pharmaceuticals is 980 monthly website visits, down 10.9% over the last three months. Auxilium Pharmaceuticals's team declined 8.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Auxilium Pharmaceuticals in the Tredyffrin Township ecosystem
The Auxilium Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SV Health Investors
Series B and later8 investors entered at this stage
Lehman Brothers
Schroders
OrbiMed- PFPerseus-Soros Biopharmaceutical Fund
CIP Capital
Sprout Group- SPSCP Partners
- BVBB Biotech Ventures
Other known investors3 additional known investors
Endo Pharmaceuticals Inc
Aisling Capital
New Leaf Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Auxilium Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Auxilium Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








